BACKGROUND: To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008-2010 in Spain. METHODS: Retrospective analysis of clinical, therapeutic, and survival data collected through filled questionnaires from patients with histologically confirmed GBM diagnosed in 19 Spanish hospitals. RESULTS: We identified 834 patients (23% aged >70 years). Surgical resection was achieved in 66% of patients, although the extent of surgery was confirmed by postoperative MRI in only 41%. There were major postoperative complications in 14% of patients, and age was the only independent predictor (Odds ratio [OR], 1.03; 95% confidence interval [CI],1.01-1.05; P = .006). After surgery, 57% received radiotherapy (RT) with concomitant and adjuvant temozolomide, 21% received other regimens, and 22% were not further treated. In patients treated with surgical resection, RT, and chemotherapy (n = 396), initiation of RT ≤42 days was associated with longer progression-free survival (hazard ratio [HR], 0.8; 95% CI, 0.64-0.99; P = .042) but not with overall survival (HR, 0.79; 95% CI, 0.62-1.00; P = .055). Only 32% of patients older than 70 years received RT with concomitant and adjuvant temozolomide. The median survival in this group was 10.8 months (95% CI, 6.8-14.9 months), compared with 17.0 months (95% CI, 15.5-18.4 months; P = .034) among younger patients with GBM treated with the same regimen. CONCLUSIONS: In a community setting, 57% of all patients with GBM and only 32% of older patients received RT with concomitant and adjuvant temozolomide. In patients with surgical resection who were eligible for chemoradiation, initiation of RT ≤42 days was associated with better progression-free survival.
BACKGROUND: To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008-2010 in Spain. METHODS: Retrospective analysis of clinical, therapeutic, and survival data collected through filled questionnaires from patients with histologically confirmed GBM diagnosed in 19 Spanish hospitals. RESULTS: We identified 834 patients (23% aged >70 years). Surgical resection was achieved in 66% of patients, although the extent of surgery was confirmed by postoperative MRI in only 41%. There were major postoperative complications in 14% of patients, and age was the only independent predictor (Odds ratio [OR], 1.03; 95% confidence interval [CI],1.01-1.05; P = .006). After surgery, 57% received radiotherapy (RT) with concomitant and adjuvant temozolomide, 21% received other regimens, and 22% were not further treated. In patients treated with surgical resection, RT, and chemotherapy (n = 396), initiation of RT ≤42 days was associated with longer progression-free survival (hazard ratio [HR], 0.8; 95% CI, 0.64-0.99; P = .042) but not with overall survival (HR, 0.79; 95% CI, 0.62-1.00; P = .055). Only 32% of patients older than 70 years received RT with concomitant and adjuvant temozolomide. The median survival in this group was 10.8 months (95% CI, 6.8-14.9 months), compared with 17.0 months (95% CI, 15.5-18.4 months; P = .034) among younger patients with GBM treated with the same regimen. CONCLUSIONS: In a community setting, 57% of all patients with GBM and only 32% of older patients received RT with concomitant and adjuvant temozolomide. In patients with surgical resection who were eligible for chemoradiation, initiation of RT ≤42 days was associated with better progression-free survival.
Authors: Normand Laperriere; Michael Weller; Roger Stupp; James R Perry; Alba A Brandes; Wolfgang Wick; Martin J van den Bent Journal: Cancer Treat Rev Date: 2012-06-19 Impact factor: 12.111
Authors: Mark A Rosenthal; Katharine J Drummond; Michael Dally; Michael Murphy; Lawrence Cher; David Ashley; Vicky Thursfield; Graham G Giles Journal: Med J Aust Date: 2006-03-20 Impact factor: 7.738
Authors: Donlin M Long; Toby Gordon; Helen Bowman; Anthony Etzel; Gregg Burleyson; Simone Betchen; Ira M Garonzik; Henry Brem Journal: Neurosurgery Date: 2003-05 Impact factor: 4.654
Authors: Stephanie E Combs; Johanna Wagner; Marc Bischof; Thomas Welzel; Florian Wagner; Jürgen Debus; Daniela Schulz-Ertner Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-29 Impact factor: 7.038
Authors: G Minniti; V De Sanctis; R Muni; F Filippone; A Bozzao; M Valeriani; M F Osti; U De Paula; G Lanzetta; V Tombolini; R Maurizi Enrici Journal: J Neurooncol Date: 2008-02-05 Impact factor: 4.130
Authors: Scott R Floyd; Ekkehard M Kasper; Erik J Uhlmann; Ekokobe Fonkem; Eric T Wong; Anand Mahadevan Journal: Front Oncol Date: 2012-10-16 Impact factor: 6.244
Authors: R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna Journal: J Neurooncol Date: 2020-06-10 Impact factor: 4.130
Authors: Alba A Brandes; Enrico Franceschi; Mario Ermani; Alicia Tosoni; Fiorenzo Albani; Roberta Depenni; Marina Faedi; Anna Pisanello; Girolamo Crisi; Benedetta Urbini; Claudio Dazzi; Luigi Cavanna; Claudia Mucciarini; Giuseppe Pasini; Stefania Bartolini; Gianluca Marucci; Luca Morandi; Elena Zunarelli; Serenella Cerasoli; Giorgio Gardini; Giovanni Lanza; Enrico Maria Silini; Silvio Cavuto; Agostino Baruzzi; A Baruzzi; F Albani; F Calbucci; R D'Alessandro; R Michelucci; A Brandes; V Eusebi; S Ceruti; E Fainardi; R Tamarozzi; E Emiliani; M Cavallo; E Franceschi; A Tosoni; M Cavallo; F Fiorica; A Valentini; R Depenni; C Mucciarini; G Crisi; E Sasso; C Biasini; L Cavanna; D Guidetti; N Marcello; A Pisanello; A M Cremonini; G Guiducci; S de Pasqua; S Testoni; R Agati; G Ambrosetto; A Bacci; E Baldin; A Baldrati; E Barbieri; S Bartolini; E Bellavista; F Bisulli; E Bonora; F Bunkheila; V Carelli; M Crisci; P Dall'Occa; D de Biase; S Ferro; C Franceschi; G Frezza; V Grasso; M Leonardi; G Marucci; V Mazzocchi; L Morandi; B Mostacci; G Palandri; E Pasini; M Pastore Trossello; A Pession; M Ragazzi; P Riguzzi; R Rinaldi; S Rizzi; G Romeo; F Spagnolli; P Tinuper; C Trocino; S Cerasoli; M Dall'Agata; M Faedi; M Frattarelli; G Gentili; A Giovannini; P Iorio; U Pasquini; G Galletti; C Guidi; W Neri; A Patuelli; S Strumia; M Casmiro; A Gamboni; F Rasi; G Cruciani; P Cenni; C Dazzi; Ar Guidi; F Zumaglini; A Amadori; G Pasini; M Pasquinelli; E Pasquini; A Polselli; A Ravasio; B Viti; M Sintini; A Ariatti; F Bertolini; G Bigliardi; P Carpeggiani; F Cavalleri; S Meletti; P Nichelli; E Pettorelli; G Pinna; E Zunarelli; F Artioli; I Bernardini; M Costa; G Greco; R Guerzoni; C Stucchi; C Iaccarino; R Rizzi; G Zuccoli; P Api; F Cartei; E Fallica; E Granieri; F Latini; G Lelli; C Monetti; V Ramponi; A Saletti; R Schivalocchi; S Seraceni; M R Tola; B Urbini; C Giorgi; E Montanari; D Cerasti; P Crafa; I Dascola; I Florindo; S Mazza; F Servadei; Em Silini; P Torelli; P Immovilli; N Morelli; C Vanzo Journal: Neurooncol Pract Date: 2014-08-28
Authors: Laia Capdevila; Sara Cros; Jose-Luis Ramirez; Carolina Sanz; Cristina Carrato; Margarita Romeo; Olatz Etxaniz; Cristina Hostalot; Ana Massuet; Jose Luis Cuadra; Salvador Villà; Carmen Balañà Journal: J Neurooncol Date: 2014-01-07 Impact factor: 4.130
Authors: C Balañá; M A Vaz; D Lopez; R de la Peñas; J M García-Bueno; M J Molina-Garrido; J M Sepúlveda; J M Cano; C Bugés; S M Sanz; J L Arranz; P Perez-Segura; A Rodriguez; J M Martin; M Benavides; M Gil Journal: Clin Transl Oncol Date: 2013-06-21 Impact factor: 3.405